Saturday, December 6, 2008

Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products

Last update: 6:58 p.m. EST Dec. 5, 2008

PALM SPRINGS, Calif., Dec 05, 2008 /PRNewswire-FirstCall via COMTEX/ -- Dynamic Alert Limited is pleased to announce that it has now identified its target markets for its pharmaceutical product line-up. The modalities will include a lozenge with some capacity for enhancing rapid onset through oromucosal absorption, topical applications, such as lotions and salves, and various products for internal use. Some products will have specific uses, while others may treat a range of problems. In keeping with both the historic medical uses of cannabis and the new scientific understanding of how cannabinoids work, Dynamic's cannabinoid pharmaceuticals will be targeting a wide-variety of serious needs such as:

1. Neuro-muscular disorders, such as MS.

2. Neuropathic pain, related to spinal cord injuries, as well as
conditions such as AIDS/HIV and the side-effects of its medications,
etc. for which opiates are not very effective.

3. Chronic pain, to reduce or eliminate patients' dependence on opiates.

4. Respiratory inflammation, related to both infections such as influenza
and to autoimmune diseases such as asthma.

5. Cancer, including pain management, control of nausea resulting from
chemotherapy as well as loss of appetite related to the disease itself.

6. Also control of cancer in conditions such as Pheochromocytoma.

7. Digestive illnesses, such as gastroesophageal reflux disease (GERDS),
Crohn's Disease and irritable bowel syndrome.

8. Dermatological infections, such as MRSA (flesh eating disease).

9. Sleep disorders.

President & CEO, Richard Cowan, states, "We are certainly pleased at the speed in which our business model is rolling out. The potential market size for some of these products is obviously very large. When multiplied by the various categories and compounded by multiple country rollouts, we are certainly undertaking a major pharmaceutical venture. Our success will be determined by the successes of our patients. Our strategy for success includes increasing the speed of bringing each product to market by using a multi-pronged approach. It is important to bear in mind that our ability to receive licensing fees for the various products will not have to wait on approval for use. Moreover, conventional measures of the various pharmaceutical markets do not offer a fair measure of the potential for cannabis-based medicines. For example, the huge cost of treating diseases such as MRSA is not measured by the cost of specific pharmaceuticals. Moreover, there is no simple metric for the value of reducing a patient's need for debilitating opiates. Consequently, we are extremely excited to bring such important medical advances to the people who need them most."

In each of these areas, cannabis has been proven to work, so Dynamic will have targeted formulations, which the Company plans to release via one or more of the four types of pharmaceutical product categories targeted:

1. Possible over-the-counter Pharmaceutical Products:

a) Non-Prescription Drugs (With disease specific claims)

b) Nutraceuticals (No disease specific claims)

2. Possible Prescription Pharmaceutical Medications:

a) Psychoactive Medications

b) Non-Psychoactive Medications

Director and Chief Science Officer, Dr. Robert Melamede, stated, "There is an enormous need for these products. Recent advances in science have opened the door to develop, produce, and commercialize a variety of effective whole plant cannabinoid-based pharmaceutical products with a wide variety of important applications. Although cannabis has been used medicinally for thousands of years, until very recently little was known about how it actually worked. Our team of scientists will develop more effective ways to produce and commercialize the production of whole plant cannabinoid-based pharmaceutical products. Even today new uses for cannabis are being found, such as the recent discovery that topical cannabis preparations can be effective against MRSA, the deadly antibiotic-resistant flesh-eating disease."

You should not place undue reliance on forward-looking statements in this press release.

This press release contains forward-looking statements that involve risks and uncertainties. Words such as "will," "anticipates," "believes," "plans," "goal," "expects," "future," "intends" and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release.

SOURCE Dynamic Alert Limited

No comments: